Database Query Results : , ,

NSCLC, Non-small Cell Lung Cancer: Click to Expand ⟱
Non-small Cell Lung Cancer
Scientific Papers found: Click to Expand⟱
5458- AF,    Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer
- in-vitro, NSCLC, NA
TrxR↓, AntiCan↓, GPx4↓, DNAdam↑, toxicity↓, eff↝,
5347- Akk,  immuno,    Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
- Human, NSCLC, NA
eff↑,
257- AL,  Cisplatin,    Allicin Overcomes Hypoxia Mediated Cisplatin Resistance in Lung Cancer Cells through ROS Mediated Cell Death Pathway and by Suppressing Hypoxia Inducible Factors
- in-vitro, NSCLC, A549
ROS↑, HIF-1↓, E-cadherin↑, N-cadherin↓, antiOx↓, Dose↝,
5361- almon,    Abstract CT190: A multicenter, open-label, single-arm, phase II study: The third generation EGFR tyrosine kinase inhibitor almonertinib for pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (APOLLO)
- Trial, NSCLC, NA
EGFR↓, OS↑, Dose↝,
5360- almon,  BEV,    Case report: Almonertinib in combination with bevacizumab for leptomeningeal metastases from epidermal growth factor receptor-mutation non-small cell lung cancer: Case series
- Case Report, NSCLC, NA
BBB↑, Dose↝, eff↓, OS↑,
5359- almon,    Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
- Trial, NSCLC, NA
eff↑, EGFR↓,
5358- almon,    Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models
- vitro+vivo, NSCLC, NA
TumMeta↓, BBB↑, EGFR↓,
5357- almon,    AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations
- Trial, NSCLC, NA
EGFR↓, eff↝, OS↑,
5131- ART/DHA,    Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cells
- in-vitro, NSCLC, ASTC-a-1
Apoptosis↑, MMP↓, Casp3↑, TumCP↓,
570- ART/DHA,    Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling
- vitro+vivo, NSCLC, A549 - vitro+vivo, NSCLC, H1299
TumCCA↑, CSCs↓, TumCI↓, TumCMig↓, TumCG↓, Wnt/(β-catenin)↓, Nanog↓, SOX2↓, OCT4↓, N-cadherin↓, Vim↓, E-cadherin↑,
4678- Ash,    Identification of Withaferin A as a Potential Candidate for Anti-Cancer Therapy in Non-Small Cell Lung Cancer
- vitro+vivo, NSCLC, H1975
ROS↑, AntiTum↑, CSCs↓, mTOR↓, STAT3↓, ChemoSen↑, Keap1↑, NRF2↓,
5180- BBR,    Berberine Targets AP-2/hTERT, NF-κB/COX-2, HIF-1α/VEGF and Cytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth
- in-vitro, NSCLC, NA
TumCMig↓, TumCP↓, Apoptosis↑, TFAP2A↓, hTERT/TERT↓, NF-kB↓, COX2↓, Hif1a↓, VEGF↓, Akt↓, p‑ERK↓, Cyt‑c↑, cl‑Casp↑, cl‑PARP↑, PI3K↓, Akt↓, Raf↓, MEK↓, ERK↓,
4675- CUR,    Curcumin improves the efficacy of cisplatin by targeting cancer stem-like cells through p21 and cyclin D1-mediated tumour cell inhibition in non-small cell lung cancer cell lines
- in-vitro, NSCLC, A549
ChemoSen↑, CSCs↓, EpCAM↓, TumCCA↓, VEGF↓, MMP9↓, toxicity↓,
4901- DCA,  Sal,    Dichloroacetate and Salinomycin as Therapeutic Agents in Cancer
- Review, NSCLC, NA
Glycolysis↓, OXPHOS↑, PDKs↓, ROS↑, Apoptosis↑, GlucoseCon↓, lactateProd↓, RadioS↑, TumAuto↑, mTOR↓, LC3s↓, p62↑, TumCG↓, OS↑, toxicity↝, ChemoSen↑, eff↑, eff↑, Ferritin↓, CSCs↓, EMT↓, ROS↑, Cyt‑c↑, Casp3↑, ER Stress↑, selectivity↑, eff↑, TumCG↓,
3215- EGCG,    Epigallocatechin gallate modulates ferroptosis through downregulation of tsRNA-13502 in non-small cell lung cancer
- in-vitro, NSCLC, A549 - in-vitro, NSCLC, H1299
TumCP↓, Ki-67↓, GPx4↓, ACSL4↑, Iron↑, MDA↑, ROS↑, Ferroptosis↑, eff↑, NRF2↑, HO-1↑,
4684- EGCG,    EGCG inhibits CSC-like properties through targeting miR-485/CD44 axis in A549-cisplatin resistant cells
- in-vivo, NSCLC, A549
miR-485↑, CSCs↓, CD44↓,
2496- Fenb,    Impairment of the Ubiquitin-Proteasome Pathway by Methyl N-(6-Phenylsulfanyl-1H-benzimidazol-2-yl)carbamate Leads to a Potent Cytotoxic Effect in Tumor Cells
- in-vitro, NSCLC, A549 - in-vitro, NSCLC, H460
TumCG↓, selectivity↑, P53↑, IKKα↑, ER Stress↑, GRP78/BiP↑, CHOP↑, ATF3↑, IRE1↑, NOXA↑, ROS↑, MMP↓, Cyt‑c↑, selectivity↑, eff↝,
4505- GLA,    Gamma linolenic acid suppresses hypoxia-induced proliferation and invasion of non-small cell lung cancer cells by inhibition of HIF1α
- in-vitro, NSCLC, Calu-1
TumCP↓, PCNA↓, Ki-67↓, MCM2↓, Bcl-2↓, BAX↑, cl‑Casp3↑, TumCMig↓, TumCI↓, Hif1a↓, VEGF↓,
4516- MAG,    Magnolol Induces Apoptosis and Suppresses Immune Evasion in Non-small Cell Lung Cancer Xenograft Models
- in-vivo, NSCLC, NA
selectivity↑, Apoptosis↑, TumCCA↑, Casp3↑, cycD1/CCND1↓, CDK4↓, VEGF↓, FOXP3↓, IDO1↓,
224- MFrot,  MF,    A pilot study of extremely low-frequency magnetic fields in advanced non-small cell lung cancer: Effects on survival and palliation of general symptoms
- Human, NSCLC, NA
PleEff↓, breath↑, Pain↓, Appetite↑, Strength↑, BowelM↑, OS↑,
4973- Nimb,    Nimbolide Exhibits Potent Anticancer Activity Through ROS-Mediated ER Stress and DNA Damage in Human Non-small Cell Lung Cancer Cells
- in-vitro, NSCLC, A549
tumCV↓, ROS↑, ER Stress↑, DNAdam↑, Apoptosis↑, eff↓,
4920- PEITC,  Cisplatin,    PEITC restores chemosensitivity in cisplatin-resistant non-small cell lung cancer by targeting c-Myc/miR-424-5p
- vitro+vivo, NSCLC, A549
TumCG↓, ChemoSen↑, cMyc↓, PI3K↓, Akt↓, mTOR↓, BioAv↝, tumCV↓, ChemoSen↑,
47- QC,    Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells
- in-vitro, NSCLC, H460 - in-vitro, NSCLC, A549
TRAIL↑, DR5↑, survivin↓,
48- QC,    Quercetin Potentiates Apoptosis by Inhibiting Nuclear Factor-kappaB Signaling in H460 Lung Cancer Cells
- in-vitro, NSCLC, H460
TRAILR↑, Casp10↑, DFF45↑, TNFR 1↑, Fas↑, NF-kB↓, IKKα↓,
5285- Ramu,  docx,    A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy
- Trial, NSCLC, NA
OS↑,
4662- RES,    A Promising Resveratrol Analogue Suppresses CSCs in Non-Small-Cell Lung Cancer via Inhibition of the ErbB2 Signaling Pathway
- in-vitro, NSCLC, A549 - in-vitro, NSCLC, H460
CSCs↓, CD133↓, OCT4↓, β-catenin/ZEB1↓, HER2/EBBR2↓, TumCP↓, PI3K↓, Akt↓, ALDH1A1↓, eff↑,
4745- SeNPs,  Chemo,    Translational Selenium Nanoparticles Promotes Clinical Non-small-cell Lung Cancer Chemotherapy via Activating Selenoprotein-driven Immune Manipulation
- Study, NSCLC, NA
Risk↓, TumCD↑, mTOR↑, AntiTum↑, ChemoSen↑,
5103- SK,    Attenuation of PI3K-Akt-mTOR Pathway to Reduce Cancer Stemness on Chemoresistant Lung Cancer Cells by Shikonin and Synergy with BEZ235 Inhibitor
- in-vitro, NSCLC, A549
CSCs↓, TumCP↓, Nanog↓, OCT4↓, p‑Akt↓, P70S6K↓, PI3K↓, mTOR↓, eff↑,
1575- statins,  Citrate,    Inhibition of Lung Cancer Growth: ATP Citrate Lyase Knockdown and Statin Treatment Leads to Dual Blockade of Mitogen-Activated Protein Kinase (MAPK) and Phosphatidylinositol-3-Kinase (PI3K)/AKT Pathways
- in-vitro, NSCLC, A549
eff↑, HMG-CoA↓, eff↑, AntiTum↑, EGFR↓, eff↑, ROS↑, EMT↓, E-cadherin↑, MUC1↑, p‑ACLY↓, p‑Akt↓, eff↑,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 29

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   ATF3↑, 1,   Ferroptosis↑, 1,   GPx4↓, 2,   HO-1↑, 1,   Iron↑, 1,   Keap1↑, 1,   MDA↑, 1,   NRF2↓, 1,   NRF2↑, 1,   OXPHOS↑, 1,   ROS↑, 8,   TrxR↓, 1,  

Metal & Cofactor Biology ⓘ

Ferritin↓, 1,  

Mitochondria & Bioenergetics ⓘ

MEK↓, 1,   MMP↓, 2,   PleEff↓, 1,   Raf↓, 1,  

Core Metabolism/Glycolysis ⓘ

p‑ACLY↓, 1,   ACSL4↑, 1,   cMyc↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 1,   HMG-CoA↓, 1,   IDO1↓, 1,   lactateProd↓, 1,   PDKs↓, 1,  

Cell Death ⓘ

Akt↓, 4,   p‑Akt↓, 2,   Apoptosis↑, 5,   BAX↑, 1,   Bcl-2↓, 1,   cl‑Casp↑, 1,   Casp10↑, 1,   Casp3↑, 3,   cl‑Casp3↑, 1,   Cyt‑c↑, 3,   DR5↑, 1,   Fas↑, 1,   Ferroptosis↑, 1,   hTERT/TERT↓, 1,   NOXA↑, 1,   survivin↓, 1,   TNFR 1↑, 1,   TRAIL↑, 1,   TRAILR↑, 1,   TumCD↑, 1,  

Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 1,  

Transcription & Epigenetics ⓘ

BowelM↑, 1,   tumCV↓, 2,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   ER Stress↑, 3,   GRP78/BiP↑, 1,   IRE1↑, 1,  

Autophagy & Lysosomes ⓘ

LC3s↓, 1,   p62↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair ⓘ

DFF45↑, 1,   DNAdam↑, 2,   P53↑, 1,   cl‑PARP↑, 1,   PCNA↓, 1,  

Cell Cycle & Senescence ⓘ

CDK4↓, 1,   cycD1/CCND1↓, 1,   TFAP2A↓, 1,   TumCCA↓, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

ALDH1A1↓, 1,   CD133↓, 1,   CD44↓, 1,   CSCs↓, 7,   EMT↓, 2,   EpCAM↓, 1,   ERK↓, 1,   p‑ERK↓, 1,   MCM2↓, 1,   mTOR↓, 4,   mTOR↑, 1,   Nanog↓, 2,   OCT4↓, 3,   P70S6K↓, 1,   PI3K↓, 4,   SOX2↓, 1,   STAT3↓, 1,   TumCG↓, 5,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

E-cadherin↑, 3,   Ki-67↓, 2,   miR-485↑, 1,   MMP9↓, 1,   MUC1↑, 1,   N-cadherin↓, 2,   TumCI↓, 2,   TumCMig↓, 3,   TumCP↓, 6,   TumMeta↓, 1,   Vim↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

EGFR↓, 5,   HIF-1↓, 1,   Hif1a↓, 2,   VEGF↓, 4,  

Barriers & Transport ⓘ

BBB↑, 2,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   FOXP3↓, 1,   IKKα↓, 1,   IKKα↑, 1,   NF-kB↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↝, 1,   ChemoSen↑, 6,   Dose↝, 3,   eff↓, 2,   eff↑, 12,   eff↝, 3,   RadioS↑, 1,   selectivity↑, 4,  

Clinical Biomarkers ⓘ

EGFR↓, 5,   Ferritin↓, 1,   HER2/EBBR2↓, 1,   hTERT/TERT↓, 1,   Ki-67↓, 2,  

Functional Outcomes ⓘ

AntiCan↓, 1,   AntiTum↑, 3,   Appetite↑, 1,   breath↑, 1,   OS↑, 6,   Pain↓, 1,   Risk↓, 1,   Strength↑, 1,   toxicity↓, 2,   toxicity↝, 1,  
Total Targets: 131

Pathway results for Effect on Normal Cells:


Total Targets: 0

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:19  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page